The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
 
Gin Wai Kwok
No Relationships to Disclose
 
Vikki Tang
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Roland Ching-Yu Leung
No Relationships to Disclose
 
Ann-Shing Lee
No Relationships to Disclose
 
Ada Law
No Relationships to Disclose
 
Joanne Wing Yan Chiu
Research Funding - Roche
 
Bryan Li
No Relationships to Disclose
 
Tan To Cheung
No Relationships to Disclose
 
Thomas Yau
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb